Regorafenib治疗恶性肿瘤的研究进展

Regnrafenib in the treatment of malignant tumor

Regorafenib（BAY73-4506）是一种口服多激酶抑制剂，可以靶向作用于血管源性、间质源性及致癌性等多种酪氨酸激酶。在体外及临床试验中Regorafenib均显示出显著的抗肿瘤活性。在恶性实体瘤特别是结直肠肿瘤的治疗中，Regorafenib的临床试验结果令人鼓舞。

Regorafenib, an oral muhi-kinase inhibitor, can inhabit a class of receptor tyrosine kinase, such as angiogenic, stromal, oncogenic and so on. Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity. The results of clinical trials are encouraging for the treatment of Refractory solid tumors, especially for colorectal carcinoma.